Urologic Oncology: Seminars and Original Investigations
Volume 27, Issue 1 , Pages 67-71 , January 2009

Outcomes for intermediate risk prostate cancer: Are there advantages for surgery, external radiation, or brachytherapy?

  • Eric A. Klein, M.D.

      Affiliations

    • Glickman Urological and Kidney Institute, Cleveland Clinic, Cleveland, OH 44195, USA
    • Taussig Cancer Center, Cleveland Clinic, Cleveland, OH 44195, USA
    • Corresponding Author InformationCorresponding author. Tel.: +1-216-444-5591; fax: +1-216-445-3532
    • ,
  • Jay Ciezki, M.D.

      Affiliations

    • Department of Radiation Oncology, Cleveland Clinic, Cleveland, OH 44195, USA
    • Taussig Cancer Center, Cleveland Clinic, Cleveland, OH 44195, USA
    • ,
  • Patrick A. Kupelian, M.D.

      Affiliations

    • M.D. Anderson Cancer Center Orlando, Orlando, FL 32806, USA
    • ,
  • Arul Mahadevan, M.D.

      Affiliations

    • Department of Radiation Oncology, Cleveland Clinic, Cleveland, OH 44195, USA
    • Taussig Cancer Center, Cleveland Clinic, Cleveland, OH 44195, USA

References 

  1. Paulson DF, Lin GH, Hinshaw W, et al. Radical surgery vs. radiotherapy for adenocarcinoma of the prostate. J Urol. 1982;128:502–504
  2. Hanks GE. More on the Uro-oncology Research Group report of radical surgery vs. radiotherapy for adenocarcinoma of the prostate. Int J Radiat Oncol Biol Phys. 1988;14:1053–1054
  3. Stamey T, Ferrari M, Schmid H. The value of serial prostate specific antigen determinations 5 years after radiotherapy: Steeply increasing values characterize 80% of patients. J Urol. 1993;150:1856–1859
  4. Zagars G, von Eschenbach A. Prognostic factors in prostate cancer: Prostate specific antigen; an important marker for prostate cancer treated by external beam radiotherapy. Cancer. 1993;72:538–548
  5. Zagars GK. Serum PSA as a tumor marker for patients undergoing definitive radiation therapy. Urol Clin North Am. 1993;20:737–747
  6. Zagars GK. Prostate specific antigen as an outcome variable for T1 and T2 prostate cancer treated by radiation therapy. J Urol. 1994;152:1786–1791
  7. Zietman AL, Shipley WU. The value of serial prostate specific antigen determinations 5 years after radiotherapy: Steeply increasing values characterize 80% of patients. J Urol. 1994;152:1564–1565Discussion 1565–6.
  8. Leibman BD, Dillioglugil O, Scardino PT, et al. Prostate-specific antigen doubling times are similar in patients with recurrence after radical prostatectomy or radiotherapy: A novel analysis. J Clin Oncol. 1998;16:2267–2271
  9. Wallace K, Fleshner N, Jewett M, et al. Impact of a multi-disciplinary patient education session on accrual to a difficult clinical trial: The Toronto experience with the surgical prostatectomy versus interstitial radiation intervention trial. J Clin Oncol. 2006;24:4158–4162
  10. Fowler FJ, McNaughton-Collins M, Albertsen PC, et al. Comparison of recommendations by urologists and radiation oncologists for treatment of clinically localized prostate cancer. J Am Med Assoc. 2000;283:3217–3222
  11. D'Amico AV, Whittington R, Malkowicz SB, et al. Predicting prostate specific antigen outcome preoperatively in the prostate specific antigen era. J Urol. 2001;166:2185–2188
  12. Scardino P. Update: NCCN Prostate Cancer Clinical Practice Guidelines. J Natl Compr Cancer Network. 2005;3(Suppl 1):S29–S33
  13. Dong F, Reuther A, Magi-Galluzzi C, et al. PSA-induced stage migration has slowed in the late PSA era? Unpublished, submitted.
  14. Klein EA, Kupelian P, Tuason L, et al. Initial dissection of the lateral fascia reduces the positive margin rate in radical prostatectomy. Urology. 1998;51:766
  15. Kupelian PA, Willoughby TR, Reddy CA, et al. Hypofractionated intensity-modulated radiotherapy (70 Gy at 2.5 Gy per fraction) for localized prostate cancer: Cleveland Clinic Experience. Int J Radiat Oncol Biol Phys. 2007;Jun 1 [Epub ahead of print]
  16. Wilkinson DA, Lee EJ, Ciezki JP, et al. Dosimetric comparison of preplanned and OR-planned prostate seed brachytherapy. Int J Rad Oncol Biol Phys. 2000;48:1241–1244
  17. Roach M, Hanks G, Thames H, et al. Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: Recommendations of the RTOG-ASTRO Phoenix Consensus Conference. Int J Radiat Oncol Biol Phys. 2006;65:965–974
  18. Litwin MS, Lubeck DP, Henning JM, et al. Differences in urologist and patient assessments of health related quality of life in men with prostate cancer: Results of the CaPSURE database. J Urol. 1998;159:1988–1992
  19. Sanda MG, Dunn RL, Michalski J, et al. Prostate size, obesity, and neoadjuvant hormone therapy affect HRQOL in a prospective, multi-center study of prostatectomy, external radiotherapy, or brachytherapy for prostate cancer. J Urol. 2007;177(Suppl 4S):589
  20. Wei JT, Dunn RL, Litwin MS, et al. Development and validation of the expanded prostate cancer index Composite (EPIC) for comprehensive assessment of health-related quality of life in men with prostate cancer. Urology. 2000;56:899–905
  21. Dong F, Jones SA, Stephenson AJ, et al. Prostate cancer volume at biopsy predicts clinically significant upgrading. J Urol, in press.
  22. Kupelian PA, Buchsbaum JC, Elshaikh M, et al. Factors affecting relapse rates after prostatectomy or radiotherapy in patients with biopsy Gleason score 8 or above: Therapeutic implications. Cancer. 2002;95:2302–2307
  23. Michalski JM, Winter K, Purdy JA, et al. Toxicity after three-dimensional radiotherapy for prostate cancer on RTOG 9406 dose Level V. Int J Radiat Oncol Biol Phys. 2005;62:706–713
  24. Moon K, Stukenborg GJ, Keim J, et al. Cancer incidence after localized therapy for prostate cancer. Cancer. 2006;107:991–998

PII: S1078-1439(08)00075-6

doi: 10.1016/j.urolonc.2008.04.001

Urologic Oncology: Seminars and Original Investigations
Volume 27, Issue 1 , Pages 67-71 , January 2009

Article Tools

* Image Usage & Resolution